Fairvalue-Calculator Fairvalue-Calculator
EN DE

Far East Bio-Tec Co (6886) Fair Value & Analysis

Consumer Defensive · TW · Market cap 1.5B TWD

Price46.00 TWD
Fair Value32.76 TWD
Upside-28.8%
Quality95/100
Evidence: High Range 22.94 TWD – 42.59 TWD

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

Far East Bio-Tec Co (6886) currently trades at 46.00 TWD, while our model-based Fair Value estimate is 32.76 TWD — implying the stock looks roughly 28.8% overvalued today. We read business quality at 95/100 (high quality), in the Consumer Defensive sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

Far East Bio-Tec Co., Ltd. manufactures and sells organic chlorella, spirulina, and dietary supplements. It also offers nutraceuticals/nutritional supplements, immune booster products, antiviral sprays, and pet supplements. The company was founded in 1976 and is based in Taipei, Taiwan.

Open the full interactive analysis →

Similar stocks

Nestlé S.A (NESN) -29% Foshan Haitian Flavouring and Food Company (603288) -28% Nestlé India Limited (NESTLEIND) -75% Grupo Bimbo, S.A. (BIMBOA) +46% Uni-President Enterprises Corp (1216) -27% Britannia Industries Limited (BRITANNIA) -62%

Frequently asked questions

Is Far East Bio-Tec Co (6886) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 32.76 TWD versus a price of 46.00 TWD — about −29% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 6886?
Our 21-model fair value for Far East Bio-Tec Co is 32.76 TWD (as of Jun 24, 2026), built from audited fundamentals. The current price is 46.00 TWD.
What is the quality score of 6886?
Far East Bio-Tec Co has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.